Skip To Main Content
Larry Saltzman on Muck Rack

Larry Saltzman

As seen in: Yahoo, The Sacramento Bee, Cell Press, Healio, San Luis Obispo Tribune, Fresno Bee, The Modesto Bee, Patient Power
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Larry

Contact Larry, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Sacramento doctor: If not for NIH funding, I wouldn’t have survived my leukemia diagnosis | Opinion Original

|
By Larry Saltzman
| The Sacramento Bee Verified
Following a terminal leukemia/lymphoma diagnosis in 2010, my physicians estimated that I would live no more than five to eight years. Today, I am seven years past that expiration date and going strong. I can thank the investments in research made by the National Institutes of Health and other non-profit organizations — notably, the Leukemia & Lymphoma Society — which have allowed me to survive my leukemia.
Open in Who Shared View Duplicates (8) Issue with article?

How Are Patients Selected for CAR T-Cell Therapy?

|
By Andrew Schorr, Larry Saltzman, David Porter
| Patient Power Verified
View next Published on April 22, 2022 Experts Explain the CAR T-Cell Therapy Decision Process With CAR T-cell therapy approved for some blood cancers and in trial for others, when do doctors recommend CAR T for patients?
Open in Who Shared Issue with article?

Anti-spike antibody response to SARS-CoV-2 booster vaccination in patients with B cell-derived hematologic malignancies

|
By Lee Greenberger, Rye Brook, Larry Saltzman, Jonathon W. Senefeld
| Cell Press Verified
Main text It has been reported that ∼15%–25% of patients with hematologic malignancies fail to make anti-spike (anti-S) antibodies in response to full dosing of SARS-CoV-2 mRNA vaccines (; ). Patients with B cell malignancies are at the highest risk of not making anti-S antibodies. Although the complete immune response in B and T cells is not fully understood, these findings suggest that seronegative patients may be vulnerable to breakthrough infections.
Open in Who Shared Issue with article?
See all 24 licensed articles (25 Total)